New psoriasis cream takes on old standby in Head-to-Head trial
NCT ID NCT07635043
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study will test whether a newer cream called tapinarof works better than the standard betamethasone cream for mild-to-moderate plaque psoriasis. About 120 adults will use one of the two creams daily for up to 12 weeks. The main goal is to see how many people get at least a 75% improvement in their psoriasis symptoms.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tapinarof cream 1% and betamethasone dipropionate 0.05% cream
What this could lead to
If tapinarof works as well or better than betamethasone, it could offer a new topical treatment option for mild-to-moderate plaque psoriasis.
What could go wrong
This is a small, early-phase trial (120 people) that hasn't started yet. Results may not apply to everyone, and tapinarof might not prove superior or could have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSORIASIS (PSO) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Pakistan institute of medical sciences(PIMS)
Islamabad, Federal, 44000, Pakistan
Contact Phone: •••-•••-•••• Email: •••••@•••••